GO:0042018 interleukin-22 receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042018 (interleukin-22 receptor activity) is a molecular function defined as the binding of interleukin-22 (IL-22) and transmission of a signal across the membrane to initiate a change in cell activity.
• The functional IL-22 receptor is a heterodimeric complex of IL22RA1 and IL10RB, which signals through JAK/STAT pathways, particularly STAT3.
• IL-22 receptor activity is central to epithelial barrier immunity, tissue regeneration, and host defense, but dysregulated signaling contributes to inflammatory diseases, cancer, and metabolic disorders [2,5,8].
• IL22RA1 expression is restricted primarily to non-hematopoietic cells such as epithelial cells and hepatocytes, while IL10RB is broadly expressed [2,3].
• Genetic and experimental studies link IL22RA1 to type 2 diabetes, hepatic steatosis, laryngeal squamous cell carcinoma, and sensory neuronal excitability [1,4,5,8].
• CRISPR-based knockout, knock-in, and overexpression models are powerful tools to dissect IL-22 receptor function in health and disease.
Description
Interleukin-22 receptor activity (GO:0042018) is a molecular function that enables a cell to bind the cytokine interleukin-22 (IL-22) and convert that binding event into an intracellular signal, thereby initiating a change in cell activity. This activity is mediated by a heterodimeric receptor complex composed of the IL-22 receptor subunit alpha 1 (IL22RA1) and the interleukin-10 receptor subunit beta (IL10RB). Unlike many cytokine receptors, the IL-22 receptor is not expressed on immune cells but is found predominantly on epithelial cells, hepatocytes, and certain stromal cells, positioning it as a key mediator of crosstalk between the immune system and peripheral tissues [2,3]. Researchers study GO:0042018 because it governs fundamental processes such as epithelial regeneration, antimicrobial defense, and metabolic homeostasis [2,6]. Dysregulated IL-22 receptor signaling has been implicated in a wide range of human diseases, including type 2 diabetes, hepatic steatosis, laryngeal squamous cell carcinoma, and severe infections such as SARS-CoV-2 and pneumococcal pneumonia [1,3,5,6,8]. Understanding the precise molecular mechanisms of IL-22 receptor activity is therefore essential for developing targeted therapies that modulate this pathway. The receptor's unique expression pattern and its ability to drive context-dependent outcomes—protective in some tissues but pathogenic in others—make it an attractive target for genetic and pharmacological interrogation [2,7]. Advances in CRISPR genome editing now allow researchers to create precise knockout, point-mutation, knock-in, and overexpression models to dissect the contribution of IL22RA1, IL10RB, and downstream effectors in relevant cell types [1,4,5].
interleukin-22 receptor activity At A Glance
| GO ID | GO:0042018 |
|---|---|
| GO term | interleukin-22 receptor activity |
| Ontology | molecular_function |
| Synonym | IL-22R, IL-22 receptor activity |
| Definition | Combining with interleukin-22 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| Major function | Binds IL-22 and initiates JAK/STAT signaling, primarily via STAT3, to regulate epithelial immunity, regeneration, and metabolism. |
| Receptor complex | Heterodimer of IL22RA1 and IL10RB. |
| Primary ligands | Interleukin-22 (IL-22), a member of the IL-10 cytokine family. |
| Tissue distribution | Predominantly non-hematopoietic cells: epithelial cells, hepatocytes, keratinocytes, pancreatic beta cells [1,2,3]. |
What Is GO:0042018?
According to the Gene Ontology, interleukin-22 receptor activity (GO:0042018) is defined as combining with interleukin-22 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. In other words, it is the function of a receptor complex that specifically recognizes IL-22 and triggers intracellular signaling cascades, leading to altered gene expression, proliferation, survival, or other cellular responses.
Why Is interleukin-22 receptor activity Important in Cell Biology?
Interleukin-22 receptor activity is a critical node at the interface of immunity and tissue homeostasis. It enables IL-22, a cytokine produced mainly by innate and adaptive immune cells, to act on epithelial and parenchymal cells, thereby orchestrating antimicrobial defense, tissue repair, and metabolic regulation. Because this receptor activity is often dysregulated in chronic inflammatory diseases, cancer, and metabolic disorders, it represents a promising therapeutic target and a key focus for basic and translational research [2,5,8].
• Drives epithelial regeneration and wound healing through STAT3 activation.
• Mediates host defense against bacterial and viral pathogens, including Streptococcus pneumoniae and SARS-CoV-2 [3,6].
• Contributes to the pathogenesis of type 2 diabetes by impairing pancreatic beta cell function.
• Promotes hepatic steatosis through modulation of oxysterol metabolism in the liver.
• Is associated with poor prognosis in laryngeal squamous cell carcinoma.
• Enhances sensory neuronal excitability via T-type calcium channels, linking IL-22 to pain and neuro-immune interactions.
• Serves as a target for synthetic biology approaches to engineer IL-22 signaling.
• Provides a model for understanding heterodimeric cytokine receptor assembly and cross-talk with gp130.
Molecular Mechanism of interleukin-22 receptor activity
Ligand binding and receptor assembly
In simple terms: IL-22 binds to a two-part receptor on the cell surface, bringing the parts together to start signaling.
Interleukin-22 (IL-22) is a secreted cytokine that binds with high affinity to the extracellular domain of IL22RA1. This binding recruits IL10RB, forming a heterodimeric signaling complex. The assembly of this complex is essential for transmitting the signal across the membrane. Structural and biochemical studies have shown that IL-22 bridges IL22RA1 and IL10RB, and that the IL10RB subunit is shared with other IL-10 family receptors, enabling potential cross-talk.
JAK activation and STAT phosphorylation
In simple terms: Once the receptor parts are together, enzymes called JAKs add phosphate groups to STAT proteins, which then move to the nucleus to turn genes on or off.
The intracellular domains of IL22RA1 and IL10RB are associated with Janus kinases (JAKs), primarily JAK1 and TYK2. Ligand-induced receptor dimerization activates these JAKs, which then phosphorylate tyrosine residues on the receptor cytoplasmic tails. These phosphotyrosines serve as docking sites for STAT proteins, mainly STAT3, which are subsequently phosphorylated, dimerize, and translocate to the nucleus to regulate target gene transcription. This JAK/STAT pathway is the canonical signaling cascade downstream of IL-22 receptor activity.
Regulation by IL-22 binding protein (IL-22BP)
In simple terms: A soluble decoy protein can soak up IL-22 and prevent it from reaching the receptor, acting as a brake on the system.
IL-22 activity is tightly regulated by a soluble decoy receptor known as IL-22 binding protein (IL-22BP), which binds IL-22 with high affinity and prevents it from interacting with the membrane-bound IL22RA1/IL10RB complex. During pneumococcal pneumonia, IL-22BP constrains IL-22 activity and host defense, and its absence alters oxidative phosphorylation gene expression. This regulation ensures that IL-22 signaling is spatially and temporally controlled.
Cross-talk with other cytokine receptors
In simple terms: The IL-22 receptor can cooperate with other receptor systems, such as the IL-6 receptor gp130, to fine-tune cellular responses.
Synthetic IL-22 signaling studies have revealed that homodimeric IL-10 receptor 2 (IL10RB) can exhibit biological activity and functionally cross-talk with the IL-6 receptor gp130. This cross-talk may diversify the cellular outcomes of IL-22 receptor activation and influence context-dependent responses in different tissues.
Tissue-specific signaling outcomes
In simple terms: The same receptor can trigger different effects depending on the cell type, such as promoting survival in epithelial cells or altering metabolism in liver and pancreas.
In pancreatic beta cells, IL22RA1 deficiency impairs beta cell function in type 2 diabetes via cytochrome b5 reductase 3, highlighting a metabolic role. In the liver, hepatic IL22RA1 deficiency promotes steatosis by modulating oxysterol metabolism. In sensory neurons, IL-22 receptor 1 stimulation enhances T-type Ca2+ channel activity through a Lyn-dependent PKA pathway, linking IL-22 to neuronal excitability. These examples illustrate how GO:0042018 can drive distinct physiological outcomes depending on the cellular context.
Key Genes Involved in GO:0042018 interleukin-22 receptor activity
The following genes and proteins are central to interleukin-22 receptor activity and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL22 | Cytokine ligand that binds and activates the IL-22 receptor | Key target for understanding receptor activation and therapeutic modulation. |
| IL22RA1 | Ligand-binding subunit of the IL-22 receptor complex | Mutations or knockout impair IL-22 signaling; linked to diabetes, steatosis, and cancer [1,5,8]. |
| IL10RB | Shared signaling subunit of the IL-22 receptor complex | Essential for signal transduction; also part of IL-10 and IL-26 receptors [2,7]. |
| JAK1 | Janus kinase that phosphorylates STAT proteins downstream of IL-22R | Critical for canonical IL-22 signaling; target for pathway inhibition. |
| TYK2 | Janus kinase associated with IL-10RB | Contributes to IL-22-induced STAT activation. |
| STAT3 | Transcription factor activated by IL-22R signaling | Mediates gene expression changes driving proliferation, survival, and regeneration. |
| IL22BP (IL22RA2) | Soluble decoy receptor that neutralizes IL-22 | Regulates IL-22 bioavailability; modulates host defense and oxidative phosphorylation. |
| SOCS3 | Negative regulator of cytokine signaling | Feedback inhibitor of IL-22-induced JAK/STAT pathway. |
| gp130 (IL6ST) | Signal-transducing subunit shared by IL-6 family receptors | Cross-talks with IL-22 receptor signaling in synthetic systems. |
| CYB5R3 | Cytochrome b5 reductase 3, downstream effector in beta cells | Mediates IL-22R-dependent beta cell function in type 2 diabetes. |
| Lyn | Tyrosine-protein kinase involved in neuronal IL-22R signaling | Links IL-22R to T-type Ca2+ channel modulation in sensory neurons. |
| PKA | Protein kinase A, downstream of Lyn in neurons | Mediates IL-22R-induced enhancement of sensory neuronal excitability. |
| CACNA1H | T-type calcium channel subunit | Effector of IL-22R signaling in sensory neurons. |
| CYP7B1 | Oxysterol-metabolizing enzyme | Modulated by hepatic IL22RA1 deficiency, contributing to steatosis. |
| REG3A | Antimicrobial peptide induced by IL-22 | Marker of IL-22R activity in epithelial cells. |
| MUC1 | Mucin induced by IL-22 in epithelial cells | Readout of IL-22R-mediated barrier function. |
| S100A8/9 | Antimicrobial proteins induced by IL-22 | Downstream effectors of IL-22R in host defense. |
| CXCL10 | Chemokine modulated by IL-22 signaling | Inflammatory mediator influenced by IL-22R activity. |
How Is interleukin-22 receptor activity Regulated?
Interleukin-22 receptor activity is regulated at multiple levels. The availability of the ligand IL-22 is controlled by IL-22 binding protein (IL-22BP), a soluble decoy receptor that prevents IL-22 from engaging the membrane-bound receptor complex. Receptor expression itself is cell-type specific and can be modulated by inflammatory cues; for example, IL22RA1 is upregulated in certain epithelial cells during infection or inflammation. Intracellularly, the JAK/STAT pathway is subject to negative feedback by SOCS proteins, particularly SOCS3, which attenuates IL-22-induced signaling. Additionally, cross-talk with other cytokine receptors such as gp130 can fine-tune the strength and duration of the signal.
interleukin-22 receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL22RA1 | Type 2 diabetes; impaired beta cell function | Pancreatic beta cell-specific knockout or point-mutation models. |
| IL22RA1 | Hepatic steatosis; oxysterol metabolism | Liver-specific knockout or overexpression in mice. |
| IL22RA1 | Laryngeal squamous cell carcinoma; poor prognosis | Knockdown or knockout in laryngeal cancer cell lines. |
| IL22RA1 | Sensory neuronal excitability; pain | Knockout or knock-in in sensory neurons. |
| IL10RB | Host defense; pneumococcal pneumonia | Knockout mice or cell lines infected with Streptococcus pneumoniae. |
Type 2 diabetes and metabolic dysfunction
Pancreatic beta cell IL22RA1 deficiency impairs beta cell function in type 2 diabetes via cytochrome b5 reductase 3, suggesting that IL-22 receptor activity is important for maintaining beta cell health and glucose homeostasis. In the liver, hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol metabolism, linking IL-22 signaling to lipid disorders.
Cancer
Increased expression of interleukin-22 and its receptor is relevant to poor prognosis in laryngeal squamous cell carcinoma, indicating that IL-22 receptor activity may promote tumor progression in this context. The JAK/STAT3 pathway downstream of IL-22R is known to drive proliferation and survival in various epithelial cancers.
Infectious diseases
IL-22 receptor activity is critical for host defense against pathogens. During pneumococcal pneumonia, IL-22 binding protein constrains IL-22 activity and host defense, and affects oxidative phosphorylation genes. In SARS-CoV-2 infection, distinct expression patterns of IL-22 receptor 1 on blood hematopoietic cells have been observed, suggesting a role in the immune response to the virus.
Neuro-immune interactions
IL-22 receptor 1-mediated stimulation of T-type Ca2+ channels enhances sensory neuronal excitability through a Lyn-dependent PKA pathway, implicating IL-22 receptor activity in pain and neurogenic inflammation.
From interleukin-22 receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL22RA1 loss impair beta cell function? | Pancreatic beta cell-specific IL22RA1 knockout. |
| Does IL22RA1 deficiency promote hepatic steatosis? | Liver-specific IL22RA1 knockout. |
| Does IL22RA1 mutation affect sensory neuronal excitability? | Point-mutation knock-in in sensory neurons. |
| Does IL22RA1 overexpression enhance tumor growth? | IL22RA1 overexpression in cancer cell lines. |
| Does IL-22BP regulate IL-22 activity in vivo? | IL-22BP knockout or overexpression models. |
| Does IL10RB cross-talk with gp130? | Synthetic receptor knock-in or overexpression systems. |
How to Study the interleukin-22 receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Validate IL22RA1/IL10RB requirement for IL-22 signaling [1,5]. |
| RNA-seq | Transcriptional changes | Identify IL-22-induced gene programs. |
| Phosphoproteomics | Protein phosphorylation events | Map JAK/STAT activation downstream of IL-22R. |
| Western blot | Protein expression and phosphorylation | Confirm STAT3 activation in response to IL-22. |
| Immunohistochemistry | Tissue expression and localization | Assess IL22RA1 expression in patient samples. |
| Calcium imaging | Intracellular calcium flux | Measure T-type Ca2+ channel activity in sensory neurons. |
| Metabolic assays | Glucose tolerance, lipid levels | Evaluate beta cell function and hepatic steatosis in knockout models [1,5]. |
| Flow cytometry | Cell surface receptor expression | Analyze IL22RA1 on blood cells during infection. |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes that modulate IL-22 receptor activity or downstream signaling. For example, knocking out IL22RA1, IL10RB, JAK1, or STAT3 in relevant cell lines followed by IL-22 stimulation and readout of STAT3 phosphorylation or target gene expression can validate pathway components [1,5].
Transcriptomic profiling
RNA-seq of cells treated with IL-22 or engineered to express mutant receptors can reveal the gene expression programs driven by GO:0042018. This approach has been used to show that IL-22BP deficiency alters oxidative phosphorylation gene expression during pneumococcal pneumonia.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics can map the signaling events downstream of IL-22 receptor activation, including JAK and STAT phosphorylation, and identify novel substrates or cross-talk nodes [2,7].
Functional assays in animal models
Tissue-specific knockout mice, such as pancreatic beta cell or liver-specific IL22RA1 knockouts, are used to study the physiological consequences of loss of IL-22 receptor activity in vivo [1,5]. These models can be combined with metabolic tests, histology, and lipid profiling.
How CRISPR Can Be Used to Study GO:0042018 interleukin-22 receptor activity
Knockout
CRISPR knockout of IL22RA1 or IL10RB in cell lines or primary cells abolishes IL-22 receptor activity, providing a clean background to study downstream signaling and cellular outcomes. For example, knockout of IL22RA1 in pancreatic beta cells impairs beta cell function, linking the receptor to type 2 diabetes. Similarly, liver-specific IL22RA1 knockout promotes hepatic steatosis.
Point Mutation
Point mutations can be introduced into IL22RA1 or IL10RB to dissect specific residues required for ligand binding, receptor dimerization, or JAK/STAT activation. Such models help distinguish between loss-of-function, gain-of-function, and separation-of-function alleles, and can be used to validate structural predictions [2,7].
Knock-in
Knock-in of tagged or reporter versions of IL22RA1 (e.g., HA-tag, GFP) allows real-time tracking of receptor expression, localization, and trafficking. Knock-in of disease-associated variants can model human mutations in relevant cell types, such as sensory neurons to study excitability.
Overexpression
Overexpression of IL22RA1 and IL10RB in cell lines can amplify IL-22 signaling and facilitate biochemical studies of the receptor complex. Overexpression models are also used to test whether increased receptor activity drives oncogenic phenotypes, as suggested by the association with poor prognosis in laryngeal squamous cell carcinoma.
How EDITGENE Supports interleukin-22 receptor activity Research
Researchers studying interleukin-22 receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes in the IL-22 receptor pathway.
Contact EDITGENE today to design your custom CRISPR model for interleukin-22 receptor activity research.
Frequently Asked Questions About interleukin-22 receptor activity
What is interleukin-22 receptor activity?
Interleukin-22 receptor activity (GO:0042018) is a molecular function that enables a cell to bind the cytokine interleukin-22 and transmit a signal across the membrane to initiate a change in cell activity.
What genes are involved in interleukin-22 receptor activity?
The core genes are IL22RA1 (ligand-binding subunit) and IL10RB (signaling subunit), which form the heterodimeric receptor complex. Downstream signaling involves JAK1, TYK2, and STAT3.
What is the GO ID for interleukin-22 receptor activity?
The Gene Ontology ID for interleukin-22 receptor activity is GO:0042018.
What diseases are associated with interleukin-22 receptor activity?
Dysregulated IL-22 receptor activity is linked to type 2 diabetes, hepatic steatosis, laryngeal squamous cell carcinoma, pneumococcal pneumonia, and SARS-CoV-2 infection [1,3,5,6,8].
How does interleukin-22 receptor signaling work?
IL-22 binds to IL22RA1, recruiting IL10RB. This activates JAK kinases, which phosphorylate STAT3, leading to its nuclear translocation and regulation of target genes.
What is the role of IL22RA1 in type 2 diabetes?
Pancreatic beta cell IL22RA1 deficiency impairs beta cell function in type 2 diabetes via cytochrome b5 reductase 3, suggesting that IL-22 receptor activity is protective for beta cells.
Can CRISPR be used to study interleukin-22 receptor activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of IL22RA1, IL10RB, and downstream effectors in various cell types [1,4,5].
What is IL-22 binding protein?
IL-22 binding protein (IL-22BP) is a soluble decoy receptor that binds IL-22 and prevents it from activating the membrane-bound IL-22 receptor, thereby regulating IL-22 activity.
How is interleukin-22 receptor activity regulated?
It is regulated by IL-22BP, receptor expression levels, negative feedback via SOCS3, and cross-talk with other cytokine receptors such as gp130 [2,6,7].
What cell types express the interleukin-22 receptor?
The IL-22 receptor is expressed predominantly on non-hematopoietic cells, including epithelial cells, hepatocytes, keratinocytes, and pancreatic beta cells [1,2,3].
Conclusion
Interleukin-22 receptor activity (GO:0042018) is a fundamental molecular function that bridges immune signals and tissue responses. Its canonical JAK/STAT3 pathway drives epithelial regeneration, host defense, and metabolic homeostasis, while dysregulation contributes to diabetes, liver disease, cancer, and infections [1,2,5,6,8]. Understanding the precise mechanisms and context-dependent outcomes of IL-22 receptor signaling is essential for developing targeted therapies. CRISPR-based genome editing offers unprecedented opportunities to dissect the genetic basis of IL-22 receptor activity. By generating knockout, point-mutation, knock-in, and overexpression models, researchers can rigorously test hypotheses and accelerate translational discoveries. EDITGENE is committed to supporting these efforts with high-quality custom cell models and bioinformatics services.
References
- 1. Yu F et al.. 2024. Pancreatic β cell interleukin-22 receptor subunit alpha 1 deficiency impairs β cell function in type 2 diabetes via cytochrome b5 reductase 3.. Cell Rep 43(12):115057 PMID: 39675006
- 2. Wolk K et al.. 2010. Biology of interleukin-22.. Semin Immunopathol 32(1):17-31 PMID: 20127093
- 3. Albayrak N et al.. 2022. Distinct Expression Patterns of Interleukin-22 Receptor 1 on Blood Hematopoietic Cells in SARS-CoV-2 Infection.. Front Immunol 13:769839 PMID: 35422799
- 4. Cai H et al.. 2024. Interleukin-22 receptor 1-mediated stimulation of T-type Ca(2+) channels enhances sensory neuronal excitability through the tyrosine-protein kinase Lyn-dependent PKA pathway.. Cell Commun Signal 22(1):307 PMID: 38831315
- 5. Huang Y et al.. 2025. Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.. Hepatology 81(5):1564-1582 PMID: 38985984
- 6. Trevejo-Nunez G et al.. 2019. Interleukin-22 (IL-22) Binding Protein Constrains IL-22 Activity, Host Defense, and Oxidative Phosphorylation Genes during Pneumococcal Pneumonia.. Infect Immun 87(11) PMID: 31451621
- 7. Mossner S et al.. 2020. Synthetic interleukin 22 (IL-22) signaling reveals biological activity of homodimeric IL-10 receptor 2 and functional cross-talk with the IL-6 receptor gp130.. J Biol Chem 295(35):12378-12397 PMID: 32611765
- 8. Ji W et al.. 2021. Increased expression of interleukin-22 and its receptor is relevant to poor prognosis in laryngeal squamous cell carcinoma: A case control trial.. Medicine (Baltimore) 100(51):e28419 PMID: 34941188
